Logo

Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrop… read more

Healthcare

Biotechnology

7 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$40.01

Price

-4.28%

-$1.79

Market Cap

$4.081b

Mid

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-33.3%

3y CAGR

-5.9%

5y CAGR
Earnings

-$377.939m

-53.4%

1y CAGR

-41.8%

3y CAGR

-31.8%

5y CAGR
EPS

-$3.29

-33.2%

1y CAGR

-15.8%

3y CAGR

-2.2%

5y CAGR
Book Value

$245.488m

$404.272m

Assets

$158.784m

Liabilities

$108.915m

Debt
Debt to Assets

26.9%

-0.3x

Debt to EBITDA
Free Cash Flow

-$300.637m

-49.5%

1y CAGR

-32.2%

3y CAGR

-24.5%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases